Latest Safety News

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Life360 has announced a $250 million convertible senior notes offering, with an option for an additional $37.5 million, aiming to bolster its balance sheet and support strategic initiatives.

Lincoln Minerals reports breakthrough metallurgical results from its Kookaburra Graphite Project, achieving ultra-high purity graphite suitable for lithium-ion battery anodes without using hazardous hydrofluoric acid. This advance supports the company’s downstream processing ambitions in South Australia.

Ioneer Ltd has announced a 308% increase in the Ore Reserve for its Rhyolite Ridge Lithium-Boron Project in Nevada, extending mine life to 95 years and confirming robust economics with low-cost lithium production and a stable boric acid revenue stream.

Tasmea Limited is set to acquire the Vertex Group, enhancing its high voltage and portable power services across regional Australia, with a deal expected to boost earnings per share by 3%.

HITIQ has secured a pivotal one-year deal with the South Metro Junior Football League, positioning its PROTEQT concussion management system at the heart of junior sports safety. This move complements existing partnerships and signals a strong push into Australia’s grassroots sports market.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.

Radiopharm Theranostics has unveiled encouraging preclinical results for its Lu177-B7H3 monoclonal antibody, RV01, paving the way for a mid-2025 Investigational New Drug submission and a Phase 1 trial later that year.

Vection Technologies has landed a $1 million contract to enhance cyber and data protection for national security intelligence, extending its footprint in the defence sector. This deal builds on previous engagements and signals potential for further growth.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Austco Healthcare has completed its strategic acquisition of New Zealand’s G&S Technologies, enhancing its healthcare communication offerings and direct sales reach in the region.

Emmerson Resources’ joint venture partner Tennant Mining has begun commercial gold production at the Nobles Project near Tennant Creek, setting the stage for potential royalty payments and future development opportunities.